Metabolic Imaging of Untreated Prostate Cancer by Positron Emission Tomography with sup 18 Fluorine-Labeled Deoxyglucose

Abstract

No AccessJournal of UrologyClinical Urology: Original Article1 Mar 1996Metabolic Imaging of Untreated Prostate Cancer by Positron Emission Tomography with sup 18 Fluorine-Labeled Deoxyglucose Peter J. Effert, Roland Bares, Stefan Handt, Johannes M. Wolff, Udalrich Bull, and Gerhard Jakse Peter J. EffertPeter J. Effert , Roland BaresRoland Bares , Stefan HandtStefan Handt , Johannes M. WolffJohannes M. Wolff , Udalrich BullUdalrich Bull , and Gerhard JakseGerhard Jakse View All Author Informationhttps://doi.org/10.1016/S0022-5347(01)66366-3AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated positron emission tomography (PET) with18 fluorine (sup 18 F)-labeled deoxyglucose for metabolic grading of untreated primary prostate cancer, and differentiation of benign and malignant prostatic disease. Materials and Methods: A total of 48 patients with untreated prostate cancer of different stages and 16 with histologically confirmed benign prostatic hyperplasia (BPH) underwent static PET after intravenous injection of 150 to 300 MBq.18 F-deoxyglucose. 18F-deoxyglucose accumulation was quantitated by calculating differential uptake ratios and prostate-to-skeletal muscle ratios. Results: Low18 F-deoxyglucose uptake was noted in the majority of primary tumors (81 percent).18 F-deoxyglucose accumulation did not correlate with increasing tumor grade or stage. There was a significant overlap in uptake values in BPH and malignant prostatic disease. A trend towards statistical significance was noted with lower prostate-to-skeletal muscle ratios in patients with BPH (p less than 0.07). Increased18 F-deoxyglucose accumulation was detected in some patients with BPH and malignant prostatic disease, as well as in those with lymph node and bone metastases of prostate cancer. Conclusions: 18 F-deoxyglucose PET does not allow for metabolic labeling in the majority of untreated primary prostate cancers. BPH and primary prostate cancer cannot be reliably differentiated on the basis of PET. Increased18 F-deoxyglucose accumulation occurs in some primary prostate tumors and in metastatic deposits of prostate cancer. References 1 : Cancer in the European Community and its member states. Eur. J. Cancer1990; 26: 1167. Google Scholar 2 Cancer Facts & Figures-1992. Atlanta: American Cancer Society1992. Google Scholar 3 : Stage D1 adenocarcinoma of the prostate. Urology1984; 23: 118. Google Scholar 4 : Morphometric and clinical studies on 68 consecutive radical prostatectomies. J. Urol.1988; 139: 1235. Link, Google Scholar 5 : Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer: results of a multi-institutional cooperative trial. New Engl. J. Med.1990; 323: 621. Google Scholar 6 : The metabolism of tumors. London: Constable1930. Google Scholar 7 : Metabolic and hemodynamic evaluation of gliomas using positron emission tomography. J. Nucl. Med.1987; 28: 1123. Google Scholar 8 : Glucose utilization by intracranial meningiomas as an index of tumor aggressivity and possibility of recurrence: a PET study. Radiology1987; 164: 521. Google Scholar 9 : Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR1988; 150: 189. Google Scholar 10 : PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J. Neurosurg.1988; 69: 830. Google Scholar 11 : The applications of PET in clinical oncology. J. Nucl. Med.1991; 32: 623. Google Scholar 12 : Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J. Nucl. Med.1993; 34: 12. Google Scholar 13 : Positron-emission-tomography (PET) with fluorine-18 labeled deoxyglucose (FDG) in prostatic cancer (PC): first results. J. Nucl. Med.1993; 34: 217P. abstract 1021. Google Scholar 14 : Maximum likelihood reconstruction for emission tomography. IEEE Trans. Med. Imaging1982; 2: 113. Google Scholar 15 : Quantitative measurements of prostatic blood flow and blood volume by positron emission tomography. J. Urol.1992; 148: 1457. Link, Google Scholar 16 : DNA synthesis, blood flow, and glucose utilization in experimental rat brain tumors. J. Neurosurg.1989; 70: 86. Google Scholar 17 : Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer1988; 61: 1776. Google Scholar 18 : F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology1994; 192: 79. Google Scholar 19 : SPECT anti-CEA immunoscintigraphy (IS) and sup 18 F-FDG PET in the evaluation of colorectal carcinoma. Eur. J. Nucl. Med.1990; 16: 410. abstract 80. Google Scholar 20 : PET studies with F-18-deoxyglucose (FDG) in patients with metastatic melanoma prior to and after therapy. J. Nucl. Med., abstract 4031990; 31: 804. Google Scholar Departments of Urology, Nuclear Medicine and Pathology, RWTH University of Aachen, Aachen, Germany© 1996 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited ByTaneja S (2018) Re: Gallium 68 PSMA-11 PET/MR Imaging in Patients with Intermediate- or High-Risk Prostate CancerJournal of Urology, VOL. 200, NO. 6, (1165-1165), Online publication date: 1-Dec-2018.Reesink D, Fransen van de Putte E, Vegt E, De Jong J, van Werkhoven E, Mertens L, Bex A, van der Poel H, van Rhijn B, Horenblas S and Meijer R (2015) Clinical Relevance of Incidental Prostatic Lesions on FDG-Positron Emission Tomography/Computerized Tomography—Should Patients Receive Further Evaluation?Journal of Urology, VOL. 195, NO. 4 Part 1, (907-912), Online publication date: 1-Apr-2016.TÓTH G, LENGYEL Z, BALKAY L, SALAH M, TRÓN L and TÓTH C (2018) DETECTION OF PROSTATE CANCER WITH 11C-METHIONINE POSITRON EMISSION TOMOGRAPHYJournal of Urology, VOL. 173, NO. 1, (66-69), Online publication date: 1-Jan-2005.Price D, Coleman R, Liao R, Robertson C, Polascik T and Degrado T (2018) Comparison of [18F]Fluorocholine and [18F]Fluorodeoxyglucose for Positron Emission Tomography of Androgen Dependent and Androgen Independent Prostate CancerJournal of Urology, VOL. 168, NO. 1, (273-280), Online publication date: 1-Jul-2002.SELTZER M, BARBARIC Z, BELLDEGRUN A, NAITOH J, DOREY F, PHELPS M, GAMBHIR S and HOH C (2018) COMPARISON OF HELICAL COMPUTERIZED TOMOGRAPHY, POSITRON EMISSION TOMOGRAPHY AND MONOCLONAL ANTIBODY SCANS FOR EVALUATION OF LYMPH NODE METASTASES IN PATIENTS WITH PROSTATE SPECIFIC ANTIGEN RELAPSE AFTER TREATMENT FOR LOCALIZED PROSTATE CANCERJournal of Urology, VOL. 162, NO. 4, (1322-1328), Online publication date: 1-Oct-1999.Hoh C, Seltzer M, Franklin J, deKernion J, Phelps M and Belldegrun A (2018) POSITRON EMISSION TOMOGRAPHY IN UROLOGICAL ONCOLOGYJournal of Urology, VOL. 159, NO. 2, (347-356), Online publication date: 1-Feb-1998. Volume 155Issue 3March 1996Page: 994-998 Advertisement Copyright & Permissions© 1996 by American Urological Association, Inc.MetricsAuthor Information Peter J. Effert More articles by this author Roland Bares More articles by this author Stefan Handt More articles by this author Johannes M. Wolff More articles by this author Udalrich Bull More articles by this author Gerhard Jakse More articles by this author Expand All Advertisement PDF DownloadLoading ...